28 R&D projects are in pharmaceuticals, five are in biotechnology and chemicals, and six in plastics.
The Office of the Chief Scientist has approved NIS 65.9 million in grants for 39 R&D projects. The companies will provide an additional NIS 96.2 million in matching funds, for a total aggregate investment of NIS 155.1 million.
Ten projects were approved for Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA), with an aggregate budget of NIS 67.1 million, including NIS 24.7 million in state grants.
18 other projects are in the pharmaceuticals: seven for D-Pharm Ltd., three for Pharmos Corp. (Nasdaq: PARS), and eight for Perrigo Company (Nasdaq:PRGO; TASE:PRGO).
The Chief Scientist also approved five projects in biotechnology and chemicals, and six projects in plastics.
Published by Globes [online], Israel business news - www.globes.co.il - on April 16, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007